Skip to main content

Alector, Inc.

ALEC
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001653087

In the last 90 days, Alector, Inc. insiders filed 0 open-market purchases and 3 sales; 140 institutions reported holding it in 13F filings for Q2 2026, worth $183.4M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Alector, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of ALEC: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders155149−6
Shares54.8M58.0M+3.17M (+5.8%)
Value$506.0M$360.9M−$145.1M (−28.7%)

New holders (13)

Institutions that held Alector, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to ALEC in Q1 2023
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.1,333,342$8.25M0.03%
UBS Asset Management Americas Inc76,432$473.1K0.00%
Profund Advisors LLC46,315$286.7K0.02%
Cubist Systematic Strategies, LLC43,010$266.2K0.00%
Verition Fund Management LLC20,521$127.0K0.00%
Trexquant Investment LP16,622$102.9K0.00%
Diversified Trust Co11,874$73.5K0.00%
Robeco Institutional Asset Management B.V.6,482$40.1K0.00%
Point72 Middle East FZE6,058$37.5K0.00%
The PNC Financial Services Group, Inc.152$9400.00%
Chesapeake Asset Management LLC150$9280.00%
Quadrant Capital Group LLC91$5640.00%
Cutler Group LP86$00.00%

Sold out (19)

Institutions that held Alector, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.